Every 8-K that Medicus Pharma Ltd. (MDCX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.
Medicus Pharma Ltd. will effect a 50-to-1 consolidation of its common shares effective October 12, 2026. Trading on a consolidated basis is expected to begin at the commencement of trading on October 12, 2026.
Every 50 issued and outstanding common shares will be exchanged for one new common share. No fractional shares will be issued; holdings that would otherwise produce a fraction will be rounded down to the next whole share, with cash paid in lieu. Voting power and share rights will remain unchanged. Proportionate adjustments will be made to exercise prices and shares issuable upon exercise or conversion of outstanding equity awards, convertible securities and warrants, and to shares under equity incentive plans. The company name and MDCX ticker will remain unchanged.
Medicus Pharma Ltd. (MDCX) reports that on September 11, 2026 it and YA II PN, Ltd. mutually agreed to terminate their Standby Equity Purchase Agreement (SEPA), which had allowed the company to issue and sell up to $15.0 million of common shares. At termination, there were no outstanding borrowings, advance notices, or common shares to be issued under the SEPA, and no fees are due by either party in connection with the termination. Yorkville Securities, LLC, an affiliate of YA II PN, Ltd., remains a sales agent under Medicus Pharma’s Equity Distribution Agreement dated December 29, 2025, as amended.
Medicus Pharma Ltd. (MDCX) reported that on September 4, 2026 it granted an aggregate of 8,529,412 restricted common shares to certain officers and employees who elected to forgo cash bonuses. These shares represent the value of approximately $1.45 million of cash bonuses, converted at $0.1705 per share, the Nasdaq Capital Market closing price on September 3, 2026.
No additional cash consideration changed hands in this issuance, which was made as a private offering exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus receives an exclusive, sublicensable, worldwide license to develop, manufacture and commercialize CD228V and related products for all human diseases.
As consideration, Medicus paid Pfizer a $12.0 million non-refundable upfront payment and must pay an additional $15.0 million on the first anniversary of the effective date. Pfizer paid Medicus a $2.0 million non-refundable Development Funding Payment to be used solely for CD228V development activities. Pfizer is eligible for development, regulatory and sales-based milestone payments that in aggregate exceed $1.0 billion, plus tiered low double-digit royalties on annual Net Sales.
Medicus retains sole authority and bears the costs for development, regulatory approval, manufacturing and commercialization, while Pfizer keeps ownership of the patent rights and an economic interest via milestones, royalties and specified participation in change-of-control, sublicensing or other strategic transactions. Pfizer also holds an option to fund all or part of development from and after the first pivotal trial, subject to a separate definitive agreement.
Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as independent auditor for the 2026 fiscal year, with 28,308,860 votes for and 756,378 votes withheld.
All nine director nominees were elected, each receiving about 15.1 million votes for and 13.5 million broker non-votes. Shareholders also approved a special resolution authorizing the board to implement a consolidation of the company’s common shares at a ratio of up to 50 pre-consolidation shares for each post-consolidation share, if the board determines such a step is necessary or desirable.
Medicus Pharma Ltd. entered into a secured note financing totaling $12,864,225 and $10,000,000 and disclosed noncompliance with Nasdaq’s market value listing standard.
The company issued a Secured Promissory Note A-1 with an 8.75% interest rate, an original issue discount of $834,225, and received $12,000,000 in cash with about $2,500,000 used to repay an existing debenture. A separate B Note of $10,000,000 at 5% interest was funded into a controlled deposit account and can be exchanged into A-type notes, releasing cash as redemptions occur. Both notes mature in 18 months and carry prepayment premiums of 110% or 115%, monthly and trading-based redemption features, and event-driven balance step-ups.
Nasdaq notified the company that its Market Value of Listed Securities has been below $35,000,000 for 30 consecutive business days and that it also fails alternative equity and income standards. Medicus has 180 days, until November 16, 2026, to regain compliance or face potential delisting, though its shares and warrants continue trading under “MDCX” and “MDCXW.”
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. entered a warrant inducement agreement with an accredited institutional holder to encourage exercise of existing warrants to buy up to 2,680,000 common shares at an amended exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional shares at $2.00 per share, split into two series expiring on June 5, 2031, with one series allowing the company to require exercise if the 10-day average VWAP reaches $10.00.
The company expects approximately $5.1 million in gross proceeds from the exercise of the existing warrants, before fees including a 6.0% cash fee to Maxim Group LLC. Medicus also reported prior sales of 680,893 common shares to Yorkville under a standby equity purchase agreement for approximately $1,500,905 in aggregate, using part of the net proceeds to prepay a portion of an outstanding debenture. The company plans to file a registration statement to permit resale of the new warrant shares.
Medicus Pharma Ltd. filed an 8-K reporting that it furnished a press release covering its financial and operating results for the quarter ended September 30, 2025, along with other corporate updates. The press release is provided as Exhibit 99.1.
The company’s securities listed on the NASDAQ Capital Market include common shares (ticker MDCX) and warrants (ticker MDCXW), with each warrant exercisable for one common share at an exercise price of $4.64 per share.
Medicus Pharma Ltd. (MDCX) reported unregistered sales of 1,088,048 common shares for approximately $2,526,364 in aggregate consideration under its Standby Equity Purchase Agreement (SEPA) with Yorkville. The sales occurred between September 8 and October 16, 2025, at prices ranging from $1.7961 to $2.7698 per share.
The company stated it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville. The shares were issued in reliance on Section 4(a)(2) of the Securities Act. The SEPA permits additional share purchases by Yorkville from time to time, subject to its conditions and limitations, and Yorkville may resell purchased shares pursuant to an effective registration statement.
Medicus Pharma Ltd. entered into a new financing deal with YA II PN, Ltd. (Yorkville), issuing a debenture with a principal amount of $8,000,000. The company received approximately $5.7 million in net proceeds after using about $1.7 million to fully repay remaining debentures from a May 2025 financing and accounting for original issue discount and fees. The debenture carries 8.00% annual interest, which can increase to 18.00% if certain events of default occur, and matures on September 17, 2026. Medicus must make monthly payments of $650,000 plus accrued interest in cash starting 45 days after issuance, with any remaining balance due at maturity. All company subsidiaries entered into a global guaranty in favor of Yorkville, and the company may redeem the debenture early in cash, in whole or in part.
Medicus Pharma Ltd. has completed its previously announced acquisition of 98.6% of Antev Ltd., a clinical-stage biotech developing Teverelix for high-risk prostate cancer and acute urinary retention. The deal consideration includes approximately US$3.0 million in cash and 1,603,164 Medicus common shares, with Antev vendors potentially earning up to $65 million in future milestone-based contingent payments tied to FDA Phase 2 and New Drug Application approvals.
The Consideration Shares were issued in a private, unregistered placement and are subject to staggered lock-up releases over roughly seven months after a resale registration statement becomes effective, with any remaining shares released by the nine-month anniversary of closing. Medicus also raised about $490,535 via Standby Equity Purchase Agreement advances by selling an aggregate 250,000 common shares to Yorkville and plans to use part of the proceeds to prepay debentures. In connection with the transaction, former Antev chairman Patrick J. Mahaffy joined Medicus’s board and received 25,000 stock options with a five-year term and a $1.94 exercise price.
Medicus Pharma Ltd. reported recent unregistered equity sales and an insider option exercise. Under its Standby Equity Purchase Agreement with Yorkville, the company sold a total of 809,654 common shares between July 30 and August 21, 2025 for approximate aggregate consideration of $1,651,464. The company plans to use part of the net proceeds to prepay a portion of debentures outstanding with Yorkville.
In addition, on August 13, 2025, the Chief Financial Officer exercised stock options for 145,000 common shares, providing the company with aggregate cash proceeds of about $156,250. The company also noted a press release describing updates on its proposed Type C Meeting with the FDA and its second quarter 2025 financial highlights.
On 4 Aug 2025 Medicus Pharma (MDCX) filed an 8-K announcing a non-binding Memorandum of Understanding (MoU) with Boston-based Helix Nanotechnologies. The parties intend to merge HelixNano’s proprietary mRNA vaccine platform with Medicus’ microneedle array (MNA) delivery technology to create thermostable, needle-free vaccines for infectious diseases.
The MoU outlines: (i) good-faith negotiations to form a joint venture for co-development and commercialisation; and (ii) an immediate collaborative project to manufacture clinical-grade MNA-loaded doses of HelixNano’s candidate HN-0001 for a Phase 1 bridging study comparing intramuscular versus intradermal delivery. Except for limited sections, the MoU is expressly non-binding; either party may withdraw until definitive agreements are executed. No financial terms, milestones, equity allocations or timelines were disclosed, and the filing contains no revenue or earnings data. A press release (Exhibit 99.1) accompanies the report, while Item 9.01 lists standard exhibit references.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed an 8-K on 14 July 2025 disclosing a capital-raising transaction structured as a warrant-exercise inducement.
Key terms of the Inducement Agreement
- The company persuaded one accredited/institutional holder to immediately exercise 1,340,000 outstanding warrants (strike = $2.80) in exchange for $3.75 million gross proceeds.
- As consideration, the holder will receive 2,680,000 new five-year warrants (two equal series) exercisable at $3.75. One series carries a forced-exercise feature if the share VWAP ≥ $10 for 10 trading days.
- Closing is expected on 14 July 2025; Maxim Group will receive a 6 % cash fee on gross proceeds.
- The company will file a Form S-1 within 120 days to register resale of the shares underlying the new warrants.
Additional equity sales under SEPA
- On 9 July and 14 July 2025 the company issued 490,000 common shares to Yorkville for $1.521 million (avg. price ≈ $3.10) under the February 2025 Standby Equity Purchase Agreement.
- Proceeds will partly prepay Yorkville debentures; future draws under the SEPA remain available.
Use of proceeds: ongoing clinical trials, general working capital and costs related to the pending acquisition of Antev Limited.
Investor takeaways
- The transactions inject roughly $5.3 million of fresh capital before fees.
- Potential dilution includes up to 2.68 million new warrant shares plus the 490 k SEPA shares already issued.
- Forced-exercise and VWAP-based adjustments could accelerate cash inflows but also amplify future share issuance.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed an amended Form 8-K (8-K/A) dated June 29, 2025 to include Exhibit 2.1—its Share Exchange Agreement with Antev Limited and certain Antev security-holders. The amendment fulfils a disclosure commitment made in the original 8-K filed June 30, 2025 and does not modify any other information previously reported.
The Share Exchange Agreement outlines the terms of a proposed transaction whereby Medicus would acquire Antev, the developer of prostate-cancer candidate Teverelix. While the full exhibit is now filed (with certain portions redacted under Reg S-K 601), the 8-K/A contains no new financial results, purchase price figures or closing timelines.
Other exhibits are unchanged: (i) Exhibit 99.1 (June 30 press release) is incorporated by reference, and (ii) Exhibit 104 provides inline XBRL for the cover page. Standard forward-looking statement language cautions investors about completion risk, clinical development uncertainty and other factors referenced in the company’s 2024 Annual Report.
Key takeaways for investors:
- The filing is largely administrative—its sole purpose is to publicly attach the Share Exchange Agreement promised in the earlier 8-K.
- No valuation metrics, consideration mix, or closing conditions are disclosed in this amendment; investors must review the newly filed exhibit for details.
- The proposed acquisition could expand Medicus’s oncology pipeline if consummated, but the 8-K/A itself provides no update on timing or probability.
Medicus Pharma (NASDAQ: MDCX) has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025. Smith, 57, brings over three decades of experience in asset management and financial operations to the emerging growth company.
Key appointment details:
- Base salary: $325,000 annually
- Stock compensation: 100,000 options at $2.60 strike price, vesting quarterly over 5 years
- Prior experience includes CEO roles at SR Asset Management and leadership positions at Aberdeen Asset Management
- Educational background: Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce
Smith initially joined as a consultant on May 27, 2025, and currently serves on the board of HazelTree Fund Services while advising Code Registry. The appointment involves no reportable related-party transactions or family relationships with other executives.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed an 8-K reporting that it has drawn the third and final tranche under the May 2, 2025 Securities Purchase Agreement with YA II PN, Ltd. (Yorkville). The company issued a $2.5 million principal debenture on June 17, 2025, delivering $2.25 million in net proceeds. Together with the two earlier debentures of $1.25 million each, Medicus has now issued the full $5 million aggregate principal authorized under the agreement, receiving $4.5 million in aggregate net cash.
The unsecured debentures are guaranteed by all subsidiaries via a global guaranty agreement. Key terms include:
- Coupon: 8.0% per annum, increasing to 18.0% if an event of default occurs.
- Maturity date: February 2, 2026 (≈ 7.5 months tenor remaining).
Item 2.03 confirms the debt constitutes a direct financial obligation. No equity conversion feature is disclosed, so the financing is presently purely debt-based, increasing leverage but avoiding immediate equity dilution. The filing does not state use of proceeds, financial covenants or repayment schedule beyond maturity.
Implications: The transaction immediately strengthens cash reserves, potentially funding pipeline or operating needs, but adds short-term debt bearing a relatively high interest rate and default step-up. Investors should assess Medicus’ liquidity profile, ability to service the 8% coupon and to refinance or repay $5 million by early 2026.